PerspectiveCancer

Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells

STKE  17 Jul 2007:
Vol. 2007, Issue 395, pp. pe38
DOI: 10.1126/stke.3952007pe38

You are currently viewing the abstract.

View Full Text

Log in


Abstract

Erythropoietin (Epo) stimulates red blood cell production by docking with its cognate receptor on the erythroid progenitor cell and triggering an array of signaling pathways that inhibit apoptosis and promote cell proliferation and differentiation. In its pharmaceutical forms, epoetin and darbepoetin, Epo is widely used to treat various anemias, including those associated with cancer. The Epo receptor is also expressed by nonhematopoietic cells, including cancer cells, and Epo exhibits a "tissue-protective" effect on nonhematopoietic tissues, possibly mediated through a novel heteroreceptor, blocking apoptosis induced by a variety of insults. The unexpected results of several clinical studies in which Epo was used to treat cancer patients have now raised the question of a potential direct growth-promoting action of Epo on cancer cells.

View Full Text